Sirtex Medical’s SIR-Spheres FlexDose Select Delivery Program Launched for Colorectal Cancer

August 5, 2024—Sirtex Medical announced the launch of its SIR-Spheres FlexDose Select delivery program to offer yttrium-90 (Y90) selective internal radiation therapy for the treatment of metastatic colorectal cancer. The program is intended to provide flexibility by enabling tailored, patient-specific dosing from a single 3-mL delivery vial.

Sirtex noted that this program marks the availability of 3-mL SIR-Spheres vials, which contain a reduced volume of microspheres (approximately 27 million compared to 44 million in the current 5-mL vials).

With up to 5 days precalibration available every day of the week, the Y90 delivery program offers a vial of SIR-Spheres designed for more selective treatment targeting, stated Sirtex.

“I have found the SIR-Spheres FlexDose program to be extremely helpful in treating my patients on a timely basis,” commented Ripal Gandhi, MD, in the company’s press release. “With this program, I can personalize the Y90 treatment for each of my patients using a product that is available every day of the week.”

Dr. Gandhi, who is a member of the Miami Cardiac & Vascular Institute and Miami Cancer Institute in Miami, Florida, and the course director for the Symposium on Clinical Interventional Oncology, added, “I applaud Sirtex for investing resources in SIR-Spheres FlexDose Select and providing more options for physicians to optimize treatment strategies for even more patients.”